PDF(Pubmed)
Abstract：
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20-99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.
摘要：
背景/目标：Molnupiravir（MOV），口服抗病毒COVID-19治疗，2021年12月在捷克共和国推出，用于治疗进展为严重疾病的高风险需要住院治疗的COVID-19患者。在这次观测中,回顾性研究,我们旨在描述非住院患者的特点和医疗资源利用情况，2022年1月1日至4月30日，成年COVID-19患者在捷克共和国服用MOV。方法：共纳入621例患者，随访28天。结果：中位年龄为68.0（20-99）岁，77.8%的人超重或肥胖，14.1%烟熏,85.7%接种了疫苗。全因住院的总累积发生率（95%CI）为0.71（0.37;1.24）/1000人年或1.9%，不同性别的比率相似，年龄组,BMI类别,多发病率类别，多药房类别，和COVID-19疫苗接种状况。在报告住院的患者中，没有观察到氧基资源，没有死亡发生。结论：这些数据描述了捷克MOV治疗患者的特征和医疗保健资源利用情况，这些患者的临床特征可能使他们患严重疾病的风险增加。
